Alexion Pharmaceuticals Inc.

(ALXN) Trade

By |

Profile

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Contact Information

Website: www.alexion.com
Email: AdverseEventReporting@alexion.com
Main Phone: +1 475-230-2596
Address: 121 Seaport Boulevard
State: MA
City / Town: Boston
Country: USA
Postal Code: 02210

Issuer Information

Exchange: NGS
CEO: Ludwig N. Hantson
Employees: 2656
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

View More

Profile

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Contact Information

Website: www.alexion.com
Email: AdverseEventReporting@alexion.com
Main Phone: +1 475-230-2596
Address: 121 Seaport Boulevard
State: MA
City / Town: Boston
Country: USA
Postal Code: 02210

Issuer Information

Exchange: NGS
CEO: Ludwig N. Hantson
Employees: 2656
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

View More
$ 108.37 $ 2.48 (2.34%)
Last Price 108.37 Change $ 2.48 Change % 2.34 Tick N/A
Bid 102.00 Bid Size 100.00 Ask 108.77 Ask Size 3,000.00
Open 106.84 High 108.59 Low 106.02 Prev Close 105.89
Last Trade Volume 1.8 mi 52 Wk Hi 141.86 52 Wk Low 92.56
Market Cap 24 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 221,290,691.00 EPS (TTM) 6.53 PE Ratio 16.70 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 15 64
Number of Buys 11 36
Number of Sells 4 28
Net Activity 24652 407343
Last 10 Buys Shares
Christopher J. Coughlin 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Last 10 Sell Shares
Brian Goff 1,000
Indrani Lall Franchini 1,000
Anne-Marie Law 1,000
John J. Orloff 1,000
Heidi L. Wagner 1,000
Julie O'Neill 1,000
Heidi L. Wagner 1,000
Brian Goff 1,000
Paul J. Clancy 1,000
Julie O'Neill 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 184 184 184 184
Low Target Price Estimate 115 115 115 115
Mean Target Price Estimate 158.29 158.29 158.29 158.29
Standard Deviation 17.09 17.09 17.09 17.09
Date of Most Recent Estimate 05/14/18 05/14/18 05/14/18 05/14/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 13 13 13 13
Moderate Buy 3 3 3 3
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.26 1.26 1.26 1.26